ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arbutus Biopharma Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.23+0.01 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Share price
−$0.18 (−4.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Arbutus Biopharma Corp grew revenue 1078.8% to $181.72M over the twelve months to Jun 30, 2026. Free cash flow was -$39.64M.
Revenue
$181.72M
+1078.8% vs. a year earlier
Operating income
$149.00M
TTM Q2 2026
Free cash flow
-$39.64M
FY2025
EPS, diluted
$0.78
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $835.30M
- P/E ratio
- 5.4
- Price to sales
- 4.60
- Price to book
- 3.23
- Dividend yield
- –
- Free cash flow yield
- -4.75%
Fundamentals
- Revenue
- $181.72M
- Net income
- $153.05M
- EPS, diluted
- $0.78
- Free cash flow
- -$39.64M
- Book value per share
- $1.31
- Diluted shares
- 197M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$181.72M+1078.8% YoY
Operating income
$149.00M
Net income
$153.05M
EPS, diluted
$0.78
Free cash flow
–
Reported periodTrailing twelve months